文献速递胸部肿瘤

LKB1活性对非小细胞肺癌PI3K/mTOR抑制敏感性的影响

The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-02-27

研究整合基因表达数据与KEGG通路进行计算机信号分析,并在LKB1野生型与缺陷型非小细胞肺癌细胞系(含CRISPR-Cas9敲除克隆)中测试mTOR、PI3K及双重抑制剂。结果显示双重抑制在LKB1突变细胞中具协同效应,敏感性高于野生型,作者认为可能是有前景的治疗策略。

要点

  • 约30%至35%的非小细胞肺癌患者存在LKB1基因失活,且对anti-PD-1/PD-L1免疫治疗反应差。
  • 体外与体内实验显示mTOR抑制与PI3K抑制在LKB1突变非小细胞肺癌细胞系中具协同效应。
  • LKB1突变细胞系对mTOR与PI3K双重抑制的敏感性高于野生型细胞系。

核心结论

  • mTOR与PI3K双重分子靶向治疗可能成为LKB1缺失肺癌患者这一特定人群的有前景治疗策略。

研究设计与样本

  • 研究采用新的计算机信号分析方法,整合基因表达数据与KEGG信号通路以识别潜在治疗靶点并对药物进行重定位。
  • 使用LKB1野生型与LKB1缺陷型非小细胞肺癌细胞系,包括由CRISPR-Cas9生成的敲除克隆。
  • 细胞系分别接受mTOR抑制剂、PI3K抑制剂及双重抑制剂处理。

主要发现

  • 计算机实验显示同时抑制mTOR与PI3K在LKB1缺陷型非小细胞肺癌中可产生协同效果。
  • 体外与体内实验显示mTOR抑制与PI3K抑制在LKB1突变非小细胞肺癌细胞系中具协同效应。
  • LKB1突变细胞系对mTOR与PI3K双重抑制的敏感性高于野生型细胞系。
  • LKB1缺陷细胞经雷帕霉素处理后Akt磷酸化的代偿性升高高于LKB1野生型细胞,这解释了两者协同效应。
  • mTOR与PI3K双重抑制在LKB1敲除细胞中引起的细胞周期调控蛋白表达下降大于LKB1野生型细胞。

临床怎么用

  • 作者认为mTOR与PI3K双重分子靶向治疗可能成为LKB1缺失肺癌患者这一特定人群的有前景治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Liver kinase B1 (LKB1), also called serine/threonine kinase 11 (STK11), is a tumor suppressor that functions as master regulator of cell growth, metabolism, survival, and polarity. Approximately 30% to 35% of patients with NSCLC possess inactivated liver kinase B1 gene (LKB1), and these patients respond poorly to anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy. Therefore, novel therapies targeting NSCLC with LKB1 loss are needed. METHODS: We used a new in silico signaling analysis method to identify the potential therapeutic targets and reposition drugs by integrating gene expression data with the Kyoto Encyclopedia of Genes and Genomes signaling pathways. LKB1 wild-type and LKB1-deficient NSCLC cell lines, including knockout clones generated by clustered regularly interspaced short pallindromic repeats-Cas9, were treated with inhibitors of mechanistic target of rapamycin kinase (mTOR) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and a dual inhibitor. RESULTS: In silico experiments showed that inhibition of both mTOR and PI3K can be synergistically effective in LKB1-deficient NSCLC. In vitro and in vivo experiments showed the synergistic effect of mTOR inhibition and PI3K inhibition in LKB1-mutant NSCLC cell lines. The sensitivity to dual inhibition of mTOR and PI3K is higher in LKB1-mutant cell lines than in wild-type cell lines. A higher compensatory increase in Akt phosphorylation after rapamycin treatment of LKB1-deficient cells than after rapamycin treatment of LKB1 wild-type cells is responsible for the synergistic effect of mTOR and PI3K inhibition. Dual inhibition of mTOR and PI3K resulted in a greater decrease in protein expression of cell cycle-regulating proteins in LKB1 knockout cells than in LKB1 wild-type cells. CONCLUSION: Dual molecular targeted therapy for mTOR and PI3K may be a promising therapeutic strategy in the specific population of patients with lung cancer with LKB1 loss.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shukuya T, Yamada T, Koenig MJ, et al. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019. PMID: 30825612. doi:10.1016/j.jtho.2019.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。